Advertisement

Picture Berlin Partner Bionnale 2021 Digital Event 650x80px
Organisation › Details

BioNTech RNA Pharmaceuticals GmbH

BioNTech RNA Pharmaceuticals GmbH is a fully-owned subsidiary company within the BioNTech AG Group. The company is a technology leader in the rapidly growing field of synthetic messenger RNA (mRNA) therapeutics. Its system is based on the precise delivery of potent, long-lived synthetic mRNA into target cells. Following delivery of the mRNA, patients’ cells produce the mRNA-encoded protein, which is the pharmacologically active product. BioNTech is currently performing clinical trials to develop the concept of tailored multivalent Mutanome Vaccines. *

 

Period Start 2014-03-06 renamed
  Group BioNTech (Group)
  Predecessor Ribological GmbH
Products Industry BIOTECH
  Industry 2 RNAi drug (RNAi therapeutic)
Persons Person Pötting, Sierk (BioNTech 201409– CFO before Sandoz Inc/Novartis + McKinsey)
  Person 2 Sahin, Ugur (BioNTech 201207 Managing Director BioNTech + Ribological GmbH)
     
Region Region Mainz
  Country Germany
  Street 12 An der Goldgrube
  City 55131 Mainz
    Address record changed: 2020-12-02
     
Basic data Employees B: 11 to 50 (2011-12-25)
     
    * Document for �About Section�: 
     
   
Record changed: 2017-04-01

Advertisement

Picture EBD Group Global Partnering Four Events One Price 650x80

More documents for BioNTech (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture [iito] Back into Ad 650x80px




» top